Who Supplies Acarbose to India from ROMANIA

As of early 2026, there are no specific free trade agreements (FTAs) or bilateral agreements between India and Romania that directly facilitate pharmaceutical trade. Both countries adhere to international standards and regulations set by organizations such as the World Trade Organization (WTO) and the World Customs Organization (WCO). Mutual recognition of Good Manufacturing Practices (GMP) and other regulatory harmonizations are typically managed through these international frameworks. While there is no dedicated bilateral agreement, the existing trade relations between India and Romania allow for the import and export of pharmaceutical products, including finished formulations containing Acarbose.

Estimating the landed cost for importing finished pharmaceutical formulations containing Acarbose from Romania to India involves several components:

1. Free on Board (FOB) Price from Romania: The FOB price is the cost of the goods at the point of origin, excluding shipping and insurance. For this estimate, let's assume an FOB price of $10,000 per shipment.

2. Sea Freight Cost: Due to current disruptions, sea freight rates have increased by approximately 50%. Assuming a pre-disruption rate of $2,000 per container, the current rate would be $3,000.

3. Marine Insurance: Typically calculated as 0.5% of the CIF (Cost, Insurance, and Freight) value. CIF value = FOB price + Sea Freight Cost = $10,000 + $3,000 = $13,000. Insurance = 0.5% of $13,000 = $65.

4. Basic Customs Duty (BCD): For HS Code 30049099, the BCD is 10% of the CIF value. BCD = 10% of $13,000 = $1,300.

5. Social Welfare Surcharge (SWS): Calculated as 10% of the BCD. SWS = 10% of $1,300 = $130.

6. Integrated Goods and Services Tax (IGST): Assuming an IGST rate of 12%, calculated on the sum of CIF value, BCD, and SWS. IGST = 12% of ($13,000 + $1,300 + $130) = 12% of $14,430 = $1,731.60.

7. Port Handling Charges: Approximately $500 per container.

8. Customs House Agent (CHA) Charges: Approximately $300 per shipment.

Total Landed Cost Calculation:

• FOB Price: $10,000
• Sea Freight: $3,000
• Marine Insurance: $65
• CIF Value: $13,000
• BCD: $1,300
• SWS: $130
• IGST: $1,731.60
• Port Handling: $500
• CHA Charges: $300

Total Landed Cost: $16,961.60

This estimate is subject to variations based on actual freight rates, insurance premiums, and applicable tax rates at the time of import.

To import Acarbose formulations into India, the following approvals are required:

1. Registration Certificate (Form 41): The foreign manufacturer must obtain a Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This involves submitting an application in Form 40, accompanied by necessary documents such as a Power of Attorney, a copy of the manufacturing license, a Free Sale Certificate, and a Certificate of Pharmaceutical Product (CPP) as per the WHO GMP certification scheme.

2. Import License (Form 10): The Indian importer must secure an Import License by submitting Form 8 to the CDSCO, along with the Registration Certificate and other required documents.

3. No Objection Certificate (NOC): For new drugs not previously approved in India, an NOC from the Drug Controller General of India (DCGI) is mandatory.

The timeline for obtaining these approvals can vary, but typically, the Registration Certificate and Import License processes may take several months.

Imported Acarbose formulations are subject to stringent quality control measures:

1. Mandatory Testing: Each batch must undergo testing at CDSCO-approved laboratories to ensure compliance with prescribed standards.

2. Certificate of Analysis (CoA): A CoA from the manufacturer, detailing the batch's quality parameters, must accompany each shipment.

3. Stability Data: Stability studies should be conducted under conditions specific to India's climate (ICH Zone IV) to demonstrate the product's shelf-life and efficacy.

4. Pharmacopoeial Standards: The formulations must meet the specifications outlined in the Indian Pharmacopoeia.

5. Port of Entry Inspection: Upon arrival, customs drug inspectors will inspect the consignment to verify compliance with regulatory requirements.

Recent policy changes affecting the import of pharmaceutical formulations into India include:

1. Minimum Import Price (MIP): In December 2025, the Indian government implemented an MIP for certain pharmaceutical inputs to protect domestic manufacturers from undercutting by foreign suppliers. While this primarily targets raw materials, it may indirectly influence the pricing and importation of finished formulations.

2. Production Linked Incentive (PLI) Scheme: Initiated in 2024, the PLI scheme aims to boost domestic production of key pharmaceutical ingredients, potentially reducing reliance on imports.

3. Bilateral Agreements: As of March 2026, there are no specific bilateral agreements between India and Romania affecting the import of pharmaceutical products.

Importers and manufacturers should stay informed about these regulatory developments to ensure compliance and strategic planning.

India's importation of finished pharmaceutical formulations containing Acarbose, such as tablets and capsules, is influenced by several factors:

1. Patented or Branded Formulations: Certain Acarbose formulations may be under patent protection or are branded products not manufactured domestically, necessitating imports to meet specific therapeutic needs.

2. Specialized Dosage Forms: Some dosage forms or combinations may not be produced within India, leading to imports to fulfill these gaps in the market.

3. Price Competitiveness: In instances where foreign manufacturers offer Acarbose formulations at more competitive prices or with superior quality, Indian companies may opt to import these products.

India possesses a robust pharmaceutical manufacturing sector with the capability to produce Acarbose formulations. However, the decision to import is often driven by the factors mentioned above. The market size for Acarbose in India is substantial, given the high prevalence of type 2 diabetes mellitus, which Acarbose is commonly prescribed to manage.

Under HS Code 30049099, which encompasses various pharmaceutical products including Acarbose formulations, India's import duty structure is as follows:

• Basic Customs Duty (BCD): 10%
• Integrated Goods and Services Tax (IGST): 12%
• Social Welfare Surcharge (SWS): 10% of the BCD

The total landed duty percentage, combining these components, amounts to approximately 23.536%.

Importers should consult the latest customs notifications to verify any exemptions or concessional duties applicable to Acarbose formulations.

India's sourcing of Acarbose formulations from Romania can be attributed to several competitive advantages:

1. Specialized Products: Romanian manufacturers may offer specific Acarbose formulations or combinations not readily available from other sources.

2. Quality Standards: Romania's pharmaceutical industry adheres to stringent European Union quality standards, ensuring high-quality products.

3. Cost Efficiency: Competitive pricing from Romanian suppliers can make imports financially viable for Indian buyers.

While Romania is a supplier, other countries such as China, Germany, and the United States also export finished Acarbose formulations to India. Romania's share in India's total Acarbose formulation imports is relatively modest, with a recorded import value of $991 USD from a single shipment.

India's importation of finished pharmaceutical formulations containing acarbose from Romania is influenced by several strategic factors:

1. Specialized Dosage Forms: Romanian manufacturers may offer acarbose formulations with specialized delivery mechanisms, such as modified-release tablets, which are not widely produced in India. These formulations can provide therapeutic advantages by improving glycemic control in patients with type 2 diabetes mellitus.

2. Technology-Licensed Products: Romania's pharmaceutical industry may possess proprietary technologies or licenses for producing acarbose formulations that meet specific international standards or patient preferences, prompting Indian companies to import these specialized products.

3. Quality Assurance: Romanian pharmaceutical products are often manufactured in compliance with stringent European Union Good Manufacturing Practices (EU GMP), ensuring high-quality standards. Indian importers may seek these products to meet regulatory requirements or to cater to markets that demand EU-certified pharmaceuticals.

4. Market Demand for Branded Formulations: Certain acarbose formulations available in Romania may be branded products with established market recognition and trust, leading Indian companies to import these to fulfill specific market segments that prefer branded medications.

When evaluating Romania as a source of finished acarbose formulations compared to other countries, several factors come into play:

Romania's unique advantage lies in offering high-quality, EU-compliant acarbose formulations at competitive prices, coupled with reliable supply chains, making it an attractive source for Indian importers.

Relying on Romania for acarbose formulations presents several supply chain risks:

1. Single-Source Dependency: Dependence on a single supplier or country can lead to vulnerabilities if disruptions occur, such as manufacturing issues or regulatory changes.

2. Currency Fluctuations: Exchange rate volatility between the Indian Rupee and the Euro can impact procurement costs, affecting pricing strategies and profit margins.

3. Regulatory Changes: Modifications in EU pharmaceutical regulations or Romanian export policies could affect the availability or compliance status of imported formulations.

4. Quality Incidents: Any quality control issues or recalls involving Romanian acarbose products could disrupt supply and damage reputations.

5. Shipping Disruptions: Logistical challenges, such as transportation strikes, port delays, or geopolitical tensions, could impede timely delivery of shipments.

To date, there have been no significant reported supply shortages of acarbose formulations from Romania to India.

To mitigate risks and optimize procurement of acarbose formulations from Romania, Indian pharmaceutical companies should consider the following strategies:

1. Dual-Sourcing Strategy: Establish relationships with multiple suppliers across different regions to reduce dependency on a single source and enhance supply chain resilience.

2. Inventory Planning: Maintain adequate buffer stock to cushion against potential supply disruptions, ensuring continuous availability of products in the market.

3. Flexible Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage cash flow effectively and reduce financial risk.

4. Minimum Order Quantities (MOQs): Assess and negotiate MOQs that align with market demand and storage capabilities to avoid overstocking or stockouts.

5. Supplier Qualification Process: Implement a rigorous supplier evaluation and qualification process, including audits and compliance checks, to ensure consistent product quality and regulatory adherence.

By adopting these measures, Indian pharmaceutical companies can enhance their procurement strategies, ensuring a stable and reliable supply of acarbose formulations to meet market demands.

To legally import Acarbose formulations into India from Romania, Indian companies must complete the following steps:

1. Obtain a Directorate General of Foreign Trade (DGFT) Import-Export Code (IEC): This unique code is mandatory for all importers and exporters in India.

2. Apply for Registration Certificate (Form 41): Submit an application in Form 40 to the Central Drugs Standard Control Organisation (CDSCO) to register the drug and manufacturing site. The Registration Certificate is issued in Form 41.

3. Secure a Drug Import License (Form 10): After obtaining the Registration Certificate, apply for an Import License by submitting Form 8 to CDSCO. The Import License is granted in Form 10.

4. Obtain a No Objection Certificate (NOC) from the Drug Controller: Depending on the specific circumstances, an NOC may be required from the Drug Controller General of India (DCGI) or the respective Zonal CDSCO office.

5. Appoint a Licensed Customs Broker: Engage a licensed customs broker to facilitate the import process and ensure compliance with customs regulations.

6. Advance Ruling for HS Code 30049099 Classification: Seek an advance ruling from the customs authorities to confirm the correct Harmonized System (HS) code classification for Acarbose formulations, ensuring accurate tariff application.

Before importing Acarbose formulations, Indian importers must obtain the following documents from their Romanian supplier:

1. Certificate of Analysis (CoA): A document detailing the product's specifications and test results, confirming its quality and compliance with agreed standards.

2. Certificate of Pharmaceutical Product (CoPP): Issued in the format recommended by the World Health Organization (WHO), this certificate establishes the status of the pharmaceutical product and the applicant in the exporting country.

3. Good Manufacturing Practice (GMP) Certificate: A certificate from the Romanian regulatory authority confirming that the manufacturing facility complies with GMP standards.

4. Drug Master File (DMF): A detailed document containing confidential information about the manufacturing, processing, and storage of the drug product.

5. Stability Data (ICH Zone IVa/IVb for India): Stability studies conducted under conditions specified for Zone IVa/IVb, relevant to India's climatic conditions, to ensure the product's shelf-life and efficacy.

6. Free Sale Certificate: A document indicating that the product is freely sold in the country of origin, demonstrating its acceptance and compliance with local regulations.

7. Manufacturer Authorization Letter: A letter from the manufacturer authorizing the supplier to distribute the product, ensuring the legitimacy of the supply chain.

Upon arrival of Acarbose formulations at an Indian port, the following quality assurance procedures are conducted:

1. CDSCO Port Drug Inspector Process: A CDSCO drug inspector examines the consignment to verify compliance with regulatory requirements and documentation.

2. Mandatory Batch Testing at Government Labs: Samples from each batch are sent to government-approved laboratories for testing to confirm compliance with specified quality standards.

3. Sample Collection Procedure: Samples are collected systematically from the consignment under the supervision of the drug inspector, ensuring representative sampling.

4. Typical Testing Timelines: The testing process usually takes several weeks, depending on the laboratory's workload and the complexity of the tests required.

5. Actions if a Batch Fails: If a batch fails quality testing, the consignment may be rejected, recalled, or subjected to further investigation. The importer may face regulatory actions, including suspension of import licenses.

6. Common Quality Issues with Romania-Origin Pharmaceuticals: Potential issues may include discrepancies in active ingredient concentration, contamination, or non-compliance with GMP standards. It is crucial to conduct thorough supplier qualification and regular audits to mitigate these risks.

To maintain ongoing compliance after importing Acarbose formulations, Indian importers should:

1. Annual CDSCO Renewal: Ensure timely renewal of the Registration Certificate and Import License as per CDSCO guidelines to maintain uninterrupted import operations.

2. Periodic Supplier Audits in Romania: Conduct regular audits of the Romanian supplier's manufacturing facilities to verify continued compliance with GMP and other quality standards.

3. Change Control Notifications: Promptly inform CDSCO of any changes in the manufacturing process, facility, or product formulation to assess the impact on product quality and regulatory compliance.

4. Pharmacovigilance Reporting: Establish a robust pharmacovigilance system to monitor and report adverse drug reactions associated with the imported Acarbose formulations, ensuring patient safety.

5. Post-Import Quality Monitoring: Implement a system for ongoing quality monitoring of the imported products, including periodic testing and market surveillance.

6. Maintaining Import Records per Drug & Cosmetics Act: Keep comprehensive records of all import activities, including documentation, testing results, and distribution logs, as mandated by the Drug & Cosmetics Act, to facilitate regulatory inspections and audits.

By adhering to these guidelines, Indian importers can ensure compliance with regulatory requirements and maintain the quality and safety of Acarbose formulations imported from Romania.